1053 related articles for article (PubMed ID: 29409351)
1. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract][Full Text] [Related]
2. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A
PLoS One; 2016; 11(12):e0166891. PubMed ID: 27907031
[TBL] [Abstract][Full Text] [Related]
4. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
[TBL] [Abstract][Full Text] [Related]
5. Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy.
Minagawa K; Al-Obaidi M; Di Stasi A
Methods Mol Biol; 2019; 1895():57-73. PubMed ID: 30539529
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
O'Hear C; Heiber JF; Schubert I; Fey G; Geiger TL
Haematologica; 2015 Mar; 100(3):336-44. PubMed ID: 25480499
[TBL] [Abstract][Full Text] [Related]
7. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
8. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
[TBL] [Abstract][Full Text] [Related]
9. Developing a membrane-proximal CD33-targeting CAR T cell.
Freeman R; Shahid S; Khan AG; Mathew SC; Souness S; Burns ER; Um JS; Tanaka K; Cai W; Yoo S; Dunbar A; Park Y; McAvoy D; Hosszu KK; Levine RL; Boelens JJ; Lorenz IC; Brentjens RJ; Daniyan AF
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38772686
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.
Rotiroti MC; Buracchi C; Arcangeli S; Galimberti S; Valsecchi MG; Perriello VM; Rasko T; Alberti G; Magnani CF; Cappuzzello C; Lundberg F; Pande A; Dastoli G; Introna M; Serafini M; Biagi E; Izsvák Z; Biondi A; Tettamanti S
Mol Ther; 2020 Sep; 28(9):1974-1986. PubMed ID: 32526203
[TBL] [Abstract][Full Text] [Related]
11. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
Front Immunol; 2020; 11():539654. PubMed ID: 33281809
[TBL] [Abstract][Full Text] [Related]
12. Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1.
Kouro T; Higashijima N; Horaguchi S; Mano Y; Kasajima R; Xiang H; Fujimoto Y; Kishi H; Hamana H; Hoshino D; Himuro H; Matsuura R; Tsuji S; Imai K; Sasada T
Int J Cancer; 2024 May; 154(10):1828-1841. PubMed ID: 38212893
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
[TBL] [Abstract][Full Text] [Related]
14. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
15. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors.
Marin V; Pizzitola I; Agostoni V; Attianese GM; Finney H; Lawson A; Pule M; Rousseau R; Biondi A; Biagi E
Haematologica; 2010 Dec; 95(12):2144-52. PubMed ID: 20713459
[TBL] [Abstract][Full Text] [Related]
16. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells.
Zheng W; O'Hear CE; Alli R; Basham JH; Abdelsamed HA; Palmer LE; Jones LL; Youngblood B; Geiger TL
Leukemia; 2018 May; 32(5):1157-1167. PubMed ID: 29479065
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.
Pizzitola I; Anjos-Afonso F; Rouault-Pierre K; Lassailly F; Tettamanti S; Spinelli O; Biondi A; Biagi E; Bonnet D
Leukemia; 2014 Aug; 28(8):1596-605. PubMed ID: 24504024
[TBL] [Abstract][Full Text] [Related]
18. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
19. Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
Pratap S; Zhao ZJ
Cancer Rep (Hoboken); 2020 Apr; 3(2):e1222. PubMed ID: 32671999
[TBL] [Abstract][Full Text] [Related]
20. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
Kim MY; Yu KR; Kenderian SS; Ruella M; Chen S; Shin TH; Aljanahi AA; Schreeder D; Klichinsky M; Shestova O; Kozlowski MS; Cummins KD; Shan X; Shestov M; Bagg A; Morrissette JJD; Sekhri P; Lazzarotto CR; Calvo KR; Kuhns DB; Donahue RE; Behbehani GK; Tsai SQ; Dunbar CE; Gill S
Cell; 2018 May; 173(6):1439-1453.e19. PubMed ID: 29856956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]